Beam Therapeutics Inc (NASDAQ: BEAM) kicked off on Tuesday, up 0.30% from the previous trading day, before settling in for the closing price of $16.62. Over the past 52 weeks, BEAM has traded in a range of $13.52-$35.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 412.30% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -0.42%. With a float of $89.62 million, this company’s outstanding shares have now reached $100.56 million.
In an organization with 483 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.06%, operating margin of -677.47%, and the pretax margin is -609.18%.
Beam Therapeutics Inc (BEAM) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 10.88%, while institutional ownership is 88.04%. The most recent insider transaction that took place on Apr 01 ’25, was worth 104,122. In this transaction Chief Legal Officer of this company sold 5,674 shares at a rate of $18.35, taking the stock ownership to the 117,294 shares. Before that another transaction happened on Apr 01 ’25, when Company’s CEO sold 30,663 for $18.35, making the entire transaction worth $562,684. This insider now owns 986,249 shares in total.
Beam Therapeutics Inc (BEAM) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -0.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.84% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Take a look at Beam Therapeutics Inc’s (BEAM) current performance indicators. Last quarter, stock had a quick ratio of 8.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.61, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.64 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.91 million. That was inferior than the volume of 1.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.26%. Additionally, its Average True Range was 1.16.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 14.48%, which indicates a significant decrease from 32.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.84% in the past 14 days, which was lower than the 82.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.53, while its 200-day Moving Average is $23.49. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $17.82. Second resistance stands at $18.97. The third major resistance level sits at $19.61. If the price goes on to break the first support level at $16.03, it is likely to go to the next support level at $15.39. The third support level lies at $14.24 if the price breaches the second support level.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
The company with the Market Capitalisation of 1.68 billion has total of 100,557K Shares Outstanding. Its annual sales at the moment are 63,520 K in contrast with the sum of -376,740 K annual income. Company’s last quarter sales were recorded 7,470 K and last quarter income was -109,270 K.
